See the DrugPatentWatch profile for Uzedy
Uzedy, a biosimilar to Ustekinumab, demonstrated comparable efficacy and safety in clinical trials [1].
How effective is Uzedy compared to the original drug?
Uzedy showed similar clinical benefits to Ustekinumab in treating conditions such as moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease [1]. In clinical studies, patients treated with Uzedy experienced comparable levels of disease control and symptom improvement as those on Ustekinumab [1].
What is the safety profile of Uzedy?
The safety profile of Uzedy is consistent with that of Ustekinumab [1]. Adverse events observed in Uzedy trials were similar to those seen with the reference product, with no new safety concerns identified [1]. Common side effects can include infections, headache, and fatigue [1].
When can Uzedy be prescribed?
Uzedy is indicated for the treatment of moderate to severe plaque psoriasis in adult and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy [2]. It is also approved for active psoriatic arthritis in adult patients and for moderately to severely active Crohn's disease in adult and pediatric patients 6 years and older who have had an inadequate response to, or are intolerant of, conventional therapy [2].
What are the key components of Uzedy's clinical trials?
The clinical development program for Uzedy included pharmacokinetic studies and comparative efficacy and safety trials [1]. These trials were designed to demonstrate analytical, clinical, and non-clinical similarity to Ustekinumab [1].
What is the patent and exclusivity status for Uzedy?
As a biosimilar, Uzedy's market entry is influenced by the patent and exclusivity of the reference product, Ustekinumab [3]. Information on specific patent expiries and biosimilar exclusivity can be found on resources like DrugPatentWatch.com [3].
What other biosimilars are available for Ustekinumab?
Several other biosimilars to Ustekinumab have been developed and are available or seeking approval in various markets. This competitive landscape is characteristic of the biosimilar industry [4].
Who manufactures Uzedy?
Uzedy is manufactured by Viatris Inc [2].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/